Literature DB >> 3257505

Effects of human recombinant tumor necrosis factor-alpha and interleukin 1 on the synthesis of glycosaminoglycan and DNA in cultured rat costal chondrocytes.

T Ikebe1, M Hirata, T Koga.   

Abstract

We examined effects of human rTNF alpha on the synthesis of glycosaminoglycan and DNA in cultured rat costal chondrocytes. The effects of human recombinant IL-1 alpha and IL-1 beta were also given attention. rTNF alpha, as well as rIL-1 alpha and rIL-1 beta, decreased the incorporation of [35S]sulfate into glycosaminoglycan to about 10% of the levels in the control. The half-maximal doses of rTNF alpha, rIL-1 alpha or rIL-1 beta required for the suppression of glycosaminoglycan synthesis (by rTNF alpha, rIL-1 alpha, and rIL-1 beta) were 2 ng/ml, 30 ng/ml, or 5 ng/ml, respectively. rTNF alpha stimulated incorporation of [3H]thymidine in the chondrocytes in a dose- and time-dependent manner. DNA synthesis was increased to about threefold over the control cultures in the presence of 1 microgram/ml rTNF alpha for 72 hr. The stimulatory effect of rTNF alpha on DNA synthesis was observed in both subconfluent and confluent cultures, whereas rIL-1 alpha and rIL-1 beta had no stimulatory activity on DNA synthesis. The addition of rTNF alpha to the cultures of chondrocytes stimulated DNA synthesis, even in medium containing no fetal calf serum. The fetal calf serum acted synergistically with rTNF alpha in increasing DNA synthesis. We propose that both TNF and IL-1 may be involved in inflammatory diseases of cartilage, and that TNF alpha, but not IL-1, may have some physiologic growth factor function for chondrocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257505

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Neutrophil-mediated cartilage injury in vitro is enhanced by tumour necrosis factor alpha.

Authors:  I C Kowanko; E J Bates; A Ferrante
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

2.  Effects of tumor necrosis factor alpha on proliferation and expression of differentiated phenotypes in rabbit costal chondrocytes in culture.

Authors:  M Enomoto; H O Pan; A Kinoshita; Y Yutani; F Suzuki; M Takigawa
Journal:  Calcif Tissue Int       Date:  1990-09       Impact factor: 4.333

3.  Modulation of extracellular matrix metabolism in rabbit articular chondrocytes and human rheumatoid synovial cells by the non-steroidal anti-inflammatory drug etodolac. II: Glycosaminoglycan synthesis.

Authors:  F Redini; A Mauviel; G Loyau; J P Pujol
Journal:  Agents Actions       Date:  1990-11

4.  Recombinant human interleukin-1 alpha and recombinant human interleukin-1 beta stimulate cartilage matrix degradation and inhibit glycosaminoglycan synthesis.

Authors:  R J Smith; N A Rohloff; L M Sam; J M Justen; M R Deibel; J C Cornette
Journal:  Inflammation       Date:  1989-08       Impact factor: 4.092

5.  Damage of cultured chondrocytes by hydrogen peroxide derived from polymorphonuclear leukocytes: a possible mechanism of cartilage degradation.

Authors:  R Saura; T Matsubara; K Hirohata; H Itoh
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

6.  Interleukin-1 beta regulation of fibroblast proteoglycan synthesis involves a decrease in versican steady-state mRNA levels.

Authors:  E E Qwarnström; H T Järveläinen; M G Kinsella; C O Ostberg; L J Sandell; R C Page; T N Wight
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

7.  Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes.

Authors:  M B Goldring; J R Birkhead; L F Suen; R Yamin; S Mizuno; J Glowacki; J L Arbiser; J F Apperley
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

8.  Synergism between muramyl dipeptide and lipopolysaccharide in the inhibition of glycosaminoglycan synthesis in cultured rat costal chondrocytes.

Authors:  T Ikebe; M Hirata; F Yanaga; T Koga
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.